These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 5784376)

  • 61. [Long-term prognosis in chronic liver diseases].
    Becker K
    Wien Med Wochenschr; 1980 Sep; 130(17):549-54. PubMed ID: 7006222
    [No Abstract]   [Full Text] [Related]  

  • 62. Chronic liver disease in central Harlem: the role of alcohol and viral hepatitis.
    Frieden TR; Ozick L; McCord C; Nainan OV; Workman S; Comer G; Lee TP; Byun KS; Patel D; Henning KJ
    Hepatology; 1999 Mar; 29(3):883-8. PubMed ID: 10051493
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Statins in liver disease: a molehill, an iceberg, or neither?
    Argo CK; Loria P; Caldwell SH; Lonardo A
    Hepatology; 2008 Aug; 48(2):662-9. PubMed ID: 18666246
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Bile acids in the therapy of chronic liver diseases].
    Sperandeo M; Varriale A; Sperandeo G; Carughi S; Lucentini L
    Recenti Prog Med; 1993 Mar; 84(3):225-30. PubMed ID: 8465104
    [TBL] [Abstract][Full Text] [Related]  

  • 65. [Therapeutic problems in acute and chronic hepatic diseases].
    De Martiis M; Patrizi P; Romagnino F; D'Ottavi R; De Martiis A
    Clin Ter; 1986 Mar; 116(6):445-56. PubMed ID: 3522060
    [No Abstract]   [Full Text] [Related]  

  • 66. [Legalon in the complex treatment of patients with hepatic stasis in chronic circulatory insufficiency].
    Krylov AA
    Vrach Delo; 1984 Mar; (3):22-3. PubMed ID: 6719894
    [No Abstract]   [Full Text] [Related]  

  • 67. [Action of silimarin in the treatment of diffuse parenchymatous hepatopathies].
    Sánchez de la Cuesta Y; Oporto Ruíz T; Martínez López J
    Rev Esp Enferm Apar Dig; 1973 Jul; 41(1):87-104. PubMed ID: 4743742
    [No Abstract]   [Full Text] [Related]  

  • 68. TNF-alpha as therapeutic target in NASH: tried, but not yet proven.
    Chitturi S; Farrell GC
    J Gastroenterol Hepatol; 2007 May; 22(5):613-4. PubMed ID: 17444846
    [No Abstract]   [Full Text] [Related]  

  • 69. [Considerations on the therapy of hepatic steatosis].
    Pisi E; Bianchi FB; Nigro F
    Minerva Med; 1969 Aug; 60(69):3117-32. PubMed ID: 5824710
    [No Abstract]   [Full Text] [Related]  

  • 70. [Membrane protectors and silymarin in hepatology therapy].
    Grossi F; Viola F
    Clin Ter; 1981 Jan; 96(1):11-23. PubMed ID: 7016408
    [No Abstract]   [Full Text] [Related]  

  • 71. [Glutathione in the treatment of chronic fatty liver diseases].
    Dentico P; Volpe A; Buongiorno R; Grattagliano I; Altomare E; Tantimonaco G; Scotto G; Sacco R; Schiraldi O
    Recenti Prog Med; 1995; 86(7-8):290-3. PubMed ID: 7569285
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Pharmaco-metabolic activity in chronic hepatopathies: influence of treatment with UDPG].
    Okolicsànyi L; Orlando R; Lirussi F; Naccarato R; Dal Brun G
    Clin Ter; 1980 May; 93(4):431-8. PubMed ID: 6998643
    [No Abstract]   [Full Text] [Related]  

  • 73. Therapeutic considerations in Reye's syndrome.
    Brown RE; Madge GE
    Pediatrics; 1971 Jul; 48(1):162-4. PubMed ID: 5561873
    [No Abstract]   [Full Text] [Related]  

  • 74. [Immunosuppressive treatment of chronic liver diseases in the clinical biochemical, immunological and histological evaluation of the liver].
    Boroń P; Szpakowicz T; Bobrowska E; Boroń-Kaczmarska A; Prokopowicz D; Borzuchowska A
    Z Gesamte Inn Med; 1981 May; 36(10):318-21. PubMed ID: 7303757
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Corticosteroids and the liver. Metabolism and indications in liver diseases].
    Uribe M; Ramos MH
    Rev Invest Clin; 1983; 35(1):71-80. PubMed ID: 6346450
    [No Abstract]   [Full Text] [Related]  

  • 76. Health-related quality of life in patients with non-alcoholic fatty liver disease.
    Dan AA; Kallman JB; Wheeler A; Younoszai Z; Collantes R; Bondini S; Gerber L; Younossi ZM
    Aliment Pharmacol Ther; 2007 Sep; 26(6):815-20. PubMed ID: 17767465
    [TBL] [Abstract][Full Text] [Related]  

  • 77. (+)-cyanidanol-3.
    Lancet; 1982 Mar; 1(8271):549. PubMed ID: 6120400
    [No Abstract]   [Full Text] [Related]  

  • 78. Hepatic prolyl hydroxylase activity in human liver disease.
    McPhie JL
    Hepatogastroenterology; 1980 Aug; 27(4):277-82. PubMed ID: 6259037
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Clinical pharmacology of hepatoprotectors].
    Chekman IS
    Lik Sprava; 2001; (1):15-9. PubMed ID: 15311683
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Drug-induced liver reactions as therapeutic principle].
    Gladtke E
    Monatsschr Kinderheilkd (1902); 1979 Mar; 127(3):122-4. PubMed ID: 423900
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.